Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of U.S. Patent for Treatment of Skin Ulcers

Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With
Issuance of U.S. Patent for Treatment of Skin Ulcers With Microcyn(R)
Technology

PETALUMA, Calif., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS), a commercial healthcare company that designs,
produces and markets innovative, safe and effective drugs, devices and
nutritional products, today announced the issuance of new U.S. patent for the
use of Microcyn® Technology in the treatment of skin ulcers. In this
application, Microcyn Technology can be delivered to skin ulcers via washing,
irrigation and soaking or through application of a wound dressing saturated in
the Microcyn Technology. According to claims allowed by the patent examiner,
the application of the Microcyn Technology via these methods will:

  *Reduce the microbial load of an infected diabetic foot ulcer;
  *Decrease the recurrence rate of an infected diabetic foot ulcer;
  *Decrease the likelihood of dehiscence of an infected diabetic foot ulcer;
  *Decrease the likelihood of amputation resulting from an infected diabetic
    foot ulcer;
  *Decrease the likelihood of systemic inflammatory response syndrome from an
    infected diabetic foot ulcer;
  *Decrease the likelihood of sepsis resulting from an infected diabetic foot
    ulcer.

Jim Schutz, CEO of Oculus said: "Healing open skin ulcers is a significant
challenge for healthcareprofessionalsaround the world. Just in the United
States, more than six million Americanseach year suffer chronic wounds
including arterial, diabetic, pressure and venous ulcers.This latest issued
patent is perfectly timed with changes to healthcare rules under the
Affordable Care Act, which penalize healthcareinstitutionsfor failure to use
best-in-class, cost-effectiveproducts, such as Microcyn. We are increasing
our efforts to convey that compelling message as broadly as possible
throughout the U.S. healthcare system." 

The latest-issued patent joins an intellectual property estate (either owned
or licensed to Oculus) that now includes 33 issued patents (seven in the U.S.
and two in the E.U.) as well 113 pending applications directed to chemical
compositions, apparatuses, methods of manufacturing and therapeutic uses.

About Oculus Innovative Sciences

Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) is a commercial healthcare
company that designs, produces and markets innovative, safe and effective
drugs, devices and nutritional products. Oculus is pioneering innovative
solutions in multiple markets for the dermatology, surgical, wound care and
animal healthcare markets, and has commercialized products in the United
States, Europe, India, China, Mexico and select Middle East countries. The
company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. More information can be
found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "increasing," "pending" and"timed,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
        
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         Director of Public and Investor Relations
         (425) 753-2105
 
Press spacebar to pause and continue. Press esc to stop.